bromopyruvate has been researched along with Bladder Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anastasiadou, E; Balafas, E; Basogianni, AS; Konstantakou, EG; Kostomitsopoulos, N; Paronis, E; Stravopodis, DJ; Syrigos, KN; Velentzas, AD; Voutsinas, GE | 1 |
1 other study(ies) available for bromopyruvate and Bladder Cancer
| Article | Year |
|---|---|
3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants.
Topics: Animals; Apoptosis; Autophagy; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Energy Metabolism; Gene Silencing; Glucose; Glucose Transporter Type 4; Humans; Mice; Mitogen-Activated Protein Kinases; Pinocytosis; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyruvates; RNA Splicing; Signal Transduction; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |